About 91% of low-grade abnormalities on Pap smears in immunocompetent young women regress within 3 years of their finding, and only about 3% progress to high-grade disease, according to a recent cohort study. The findings provide strong support for the position that subjecting all young women with low-grade squamous intraepithelial lesions (LSIL) to colposcopy is unwarranted.
About 91% of low-grade abnormalities on Pap smears in immunocompetent young women regress within 3 years of their finding, and only about 3% progress to high-grade disease, according to a recent cohort study. The findings provide strong support for the position that subjecting all young women with low-grade squamous intraepithelial lesions (LSIL) to colposcopy is unwarranted.
The longitudinal study of human papillomavirus (HPV) infection included females between 13 and 22 years of age. The researchers found that of 187 women with LSIL, 61% regressed by 12 months and 91% regressed by 36 months. They found no associations between regression and HPV status at baseline, sexual behavior, contraceptive use, substance or cigarette use, incident sexually transmitted infection, or biopsy.
While the study was not designed to examine factors that would predict regression, a negative HPV test at a subsequent visit was a good indicator that LSIL regressed. HPV status at the current visit was associated with rate of regression, whether infection was caused by one or more viral types (relative hazard=0.3 and 0.14, respectively). Multiple HPV types had the strongest association with LSIL persistence, a finding that the researchers felt deserved further investigation.
The author of an accompanying editorial agreed, writing that the purpose of screening is to prevent cervical cancer by detecting lesions that will probably become cancerous, and that the psychosexual damage associated with colposcopy in young women outweighs any provided benefit.
Moscicki AB, Shiboski S, Hills NK, et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet. 2004;364:1678-1683.
Szarewski A, Sasieni P. Cervical screening in adolescents-at least do no harm. Lancet. 2004;364:1642-1643.
Unlocking HPV prevention: Insights from 2022 data on vaccination trends
May 14th 2024Explore the latest findings revealing vaccination rates among children aged 9 to 17 years, uncovering demographic disparities and highlighting the crucial role of vaccination in combating human papillomavirus infections and related health risks.
Read More
Prenatal cannabis and nicotine use linked to adverse pregnancy outcomes
May 14th 2024A recent study highlights the heightened risks of maternal and neonatal morbidity and mortality associated with combined cannabis and nicotine use during pregnancy, urging further investigation into their impact on short- and long-term outcomes.
Read More
Understanding pediatric STIs: Trends, management, and more
May 10th 2024Dive into the rising prevalence of sexually transmitted infections among adolescents and young adults, exploring educational gaps, vaccination rates, and the imperative need for open conversations between patients and health care providers to combat stigma and enhance preventive care.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More